ASRT

Assertio Holdings Inc. (ASRT) | Rumor.io

Assertio Holdings

ASRT

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)80%

Price to earnings ratio1.2

Market capitalization151.9M

Earnings per share-5.55

Dividend yield (TTM)—

Revenue (annual)118.7M

Net income (annual)-30.4M

Social

What share of all stock conversation is about ASRT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

May 13

Assertio Holdings, Inc. (ASRT) has agreed to be acquired by Zydus Worldwide DMCC for $23.50 per share in an all-cash tender offer worth $166.4 million.
The offer represents a 30.6% premium to the original agreement with Garda Therapeutics and a 75.8% premium to the unaffected price.
Zydus must commence the tender offer within 5 business days and the deal can terminate if the acquisition does not close by July 12, with a termination fee of $6,263,180.

Generated by AI

Sentiment

Of the messages about ASRT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	87.42% +4.64
Bearish	—	—	—	12.58% -4.64

Bullish· Nov 11

The company has $93 million in cash and $40 million in debt, making it a highly cash-rich business with a significant margin of safety.
The company's Rolvedon product has already generated $38 million in revenue, which is a stellar performance considering its market capitalization, and could be even more exciting if it were to receive same-day administration approval.
The company's stock is undervalued, with a market capitalization of $80 million, and could be worth significantly more, potentially even double its current level, given its revenue and cash flow generation.

Bearish· Nov 8

The company's financials haven't changed since July, and the short report's claims of product-related fraud are unfounded.
The short report's author, Buxton Helmsley, has a conflict of interest and may have been motivated by a desire to gain revenge against the company's board.
The company's ability to generate free cash flow (FCF) and its potential for a buyback could help it overcome the current short selling pressure.

Generated by AI

Topics

Of the messages about ASRT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	0%	16.1%
Announcements	—	—	100%	48.74%
Controversies	—	—	0%	7.83%
Earnings	—	—	0%	4.28%
Macro	—	—	0%	15.81%
Technical Analysis	—	—	0%	7.24%

Earnings· Mar 11

Assertio Holdings, Inc. (ASRT) reported Q4 2020 earnings with a GAAP EPS of -$0.20 and revenue of $30.17M, beating analyst consensus estimates.
The company's Q4 2020 sales decreased by 49.68% compared to the same period last year, while quarterly losses decreased by 42.86% compared to the same period last year.
Assertio is scheduled to report earnings on March 11, 2021, after market close, with a consensus EPS forecast of -$0.04 for the quarter.

Announcements· May 13

Assertio Holdings ($ASRT) is being acquired by Zydus Worldwide DMCC for $23.50 per share in cash, valuing the company at approximately $166.4 million.
The all-cash tender offer represents a 75.8% premium to Assertio's unaffected price and a 30.6% premium to the original agreement with Garda Therapeutics.
The acquisition is expected to close in Q2 2026, pending majority tender and customary conditions, with a termination fee of $6,263,180 if the deal does not close by July 12.

Technical Analysis· May 7

A potential breakout for $ASRT is predicted to occur at $0.65 - $0.70.
An inverted head and shoulder chart pattern is identified on the chart, which could signal a long-term trend leg up to $3.30.
The RSI is expected to catch up, and patience is advised, with a possible break at $0.58 and a subsequent price increase.

Generated by AI

Community

Of the messages about ASRT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	8.16%	62.18%
Newcomers	—	—	91.84%	37.82%

Regulars· May 13

Zydus Lifesciences has agreed to acquire Assertio Holdings for $166.4 million, or $23.50 per share, in an all-cash tender offer.
The deal represents a 30.6% premium to the original agreement with Garda Therapeutics and a 75.8% premium to the unaffected price.
The acquisition will take Assertio Holdings private, with Zydus offering a share exchange or cash for shareholders who may not want to sell.

Newcomers· May 4

Assertio Holdings (ASRT) shareholders have secured a definitive, all-cash exit with Garda Therapeutics' revised tender offer of $21.80 per share, eliminating the contingent value right.
The revised merger agreement with Garda Therapeutics provides a 21% increase from the original offer, with the new price representing a 63% premium to Assertio's unaffected price.
The deal is expected to close in Q2, with Garda committing to a minimum of $95 million in net cash to close the acquisition, and a total consideration of $153.2 million.

Generated by AI

The mean of analysts' price targets for Archer Aviation (ACHR) points to a 93.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

2mo agoYahoo Finance

Also Discussed

Investors talking about ASRT also mention

#	Name	Attention
1	Castor Maritime Inc.CTRM	0%0
2	Citius Pharmaceuticals, Inc.CTXR	0%0
3	Collegium Pharmaceutical, Inc.COLL	0%0
4	It Tech Packaging Inc.ITP	0%0
5	CFMS - Conformis, Inc.	——
6	SPPI - Spectrum Pharmaceuticals, Inc.	——
7	AEZS - Aeterna Zentaris Inc.	——
8	TherapeuticsMD, Inc.TXMD	0%new
9	AAU - Almaden Minerals Ltd.	——
10	GSV - Gold Standard Ventures Corp	——

Assertio Holdings Inc.

Healthcare
Drug Manufacturers - Specialty & Generic

Assertio Holdings Inc. is a leading commercial pharmaceutical company that brings differentiated branded prescription products to patients across key therapeutic areas. It maintains a robust portfolio focused on neurology, inflammation, pain management, oncology, and hospital products, including medications such as INDOCIN for treating rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, gouty arthritis, and acute painful shoulder; Sympazan, a benzodiazepine for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome; Otrexup, SPRIX, CAMBIA, and Zipsor; as well as Rolvedon in oncology following strategic business development. The company specializes in acquiring, licensing, and optimizing commercial-stage assets through an acquisition-driven model, emphasizing targeted marketing and lifecycle management to serve patients primarily in the United States. Founded in 1995 and headquartered in Lake Forest, Illinois, Assertio Holdings Inc. plays a vital role in the specialty pharmaceuticals sector by providing established, high-margin products in neuroscience, immunology, and oncology.

Website

Location

100 South Saunders Road

Lake Forest, IL, 60045

United States

Social

What share of all stock conversation is about ASRT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

May 13

Assertio Holdings, Inc. (ASRT) has agreed to be acquired by Zydus Worldwide DMCC for $23.50 per share in an all-cash tender offer worth $166.4 million.
The offer represents a 30.6% premium to the original agreement with Garda Therapeutics and a 75.8% premium to the unaffected price.
Zydus must commence the tender offer within 5 business days and the deal can terminate if the acquisition does not close by July 12, with a termination fee of $6,263,180.

Generated by AI

Sentiment

Of the messages about ASRT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	87.42% +4.64
Bearish	—	—	—	12.58% -4.64

Bullish· Nov 11

The company has $93 million in cash and $40 million in debt, making it a highly cash-rich business with a significant margin of safety.
The company's Rolvedon product has already generated $38 million in revenue, which is a stellar performance considering its market capitalization, and could be even more exciting if it were to receive same-day administration approval.
The company's stock is undervalued, with a market capitalization of $80 million, and could be worth significantly more, potentially even double its current level, given its revenue and cash flow generation.

Bearish· Nov 8

The company's financials haven't changed since July, and the short report's claims of product-related fraud are unfounded.
The short report's author, Buxton Helmsley, has a conflict of interest and may have been motivated by a desire to gain revenge against the company's board.
The company's ability to generate free cash flow (FCF) and its potential for a buyback could help it overcome the current short selling pressure.

Generated by AI

Topics

Of the messages about ASRT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	0%	16.1%
Announcements	—	—	100%	48.74%
Controversies	—	—	0%	7.83%
Earnings	—	—	0%	4.28%
Macro	—	—	0%	15.81%
Technical Analysis	—	—	0%	7.24%

Earnings· Mar 11

Assertio Holdings, Inc. (ASRT) reported Q4 2020 earnings with a GAAP EPS of -$0.20 and revenue of $30.17M, beating analyst consensus estimates.
The company's Q4 2020 sales decreased by 49.68% compared to the same period last year, while quarterly losses decreased by 42.86% compared to the same period last year.
Assertio is scheduled to report earnings on March 11, 2021, after market close, with a consensus EPS forecast of -$0.04 for the quarter.

Announcements· May 13

Assertio Holdings ($ASRT) is being acquired by Zydus Worldwide DMCC for $23.50 per share in cash, valuing the company at approximately $166.4 million.
The all-cash tender offer represents a 75.8% premium to Assertio's unaffected price and a 30.6% premium to the original agreement with Garda Therapeutics.
The acquisition is expected to close in Q2 2026, pending majority tender and customary conditions, with a termination fee of $6,263,180 if the deal does not close by July 12.

Technical Analysis· May 7

A potential breakout for $ASRT is predicted to occur at $0.65 - $0.70.
An inverted head and shoulder chart pattern is identified on the chart, which could signal a long-term trend leg up to $3.30.
The RSI is expected to catch up, and patience is advised, with a possible break at $0.58 and a subsequent price increase.

Generated by AI

Community

Of the messages about ASRT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	8.16%	62.18%
Newcomers	—	—	91.84%	37.82%

Regulars· May 13

Zydus Lifesciences has agreed to acquire Assertio Holdings for $166.4 million, or $23.50 per share, in an all-cash tender offer.
The deal represents a 30.6% premium to the original agreement with Garda Therapeutics and a 75.8% premium to the unaffected price.
The acquisition will take Assertio Holdings private, with Zydus offering a share exchange or cash for shareholders who may not want to sell.

Newcomers· May 4

Assertio Holdings (ASRT) shareholders have secured a definitive, all-cash exit with Garda Therapeutics' revised tender offer of $21.80 per share, eliminating the contingent value right.
The revised merger agreement with Garda Therapeutics provides a 21% increase from the original offer, with the new price representing a 63% premium to Assertio's unaffected price.
The deal is expected to close in Q2, with Garda committing to a minimum of $95 million in net cash to close the acquisition, and a total consideration of $153.2 million.

Generated by AI

Assertio Holdings

Social

May 13

Sentiment

Bullish· Nov 11

Bearish· Nov 8

Topics

Earnings· Mar 11

Announcements· May 13

Technical Analysis· May 7

Community

Regulars· May 13

Newcomers· May 4

News

Wall Street Analysts Predict a 93.63% Upside in Archer Aviation (ACHR): Here's What You Should Know

Also Discussed

Assertio Holdings Inc.

Company Information

Location

News

Wall Street Analysts Predict a 93.63% Upside in Archer Aviation (ACHR): Here's What You Should Know

Also Discussed

Social

May 13

Sentiment

Bullish· Nov 11

Bearish· Nov 8

Topics

Earnings· Mar 11

Announcements· May 13

Technical Analysis· May 7

Community

Regulars· May 13

Newcomers· May 4